These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28511068)

  • 1. Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968-2000.
    Huzair F; Sturdy S
    Stud Hist Philos Biol Biomed Sci; 2017 Aug; 64():11-21. PubMed ID: 28511068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuban Prophylactic and Therapeutic Vaccines for Controlling Hepatitis B.
    Pentón-Arias E; Aguilar-Rubido JC
    MEDICC Rev; 2021 Jan; 23(1):21-29. PubMed ID: 33780419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indian vaccine innovation: the case of Shantha Biotechnics.
    Chakma J; Masum H; Perampaladas K; Heys J; Singer PA
    Global Health; 2011 Apr; 7():9. PubMed ID: 21507259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalent inactivated hepatitis A and recombinant hepatitis B vaccine.
    Beran J
    Expert Rev Vaccines; 2007 Dec; 6(6):891-902. PubMed ID: 18377352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer directions in vaccine development and utilization.
    Hilleman MR
    J Infect Dis; 1985 Mar; 151(3):407-19. PubMed ID: 2982958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B.
    Joung YH; Park SH; Moon KB; Jeon JH; Cho HS; Kim HS
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockbuster expectations for hepatitis B therapeutic vaccine.
    Elvidge S
    Nat Biotechnol; 2015 Aug; 33(8):789. PubMed ID: 26252120
    [No Abstract]   [Full Text] [Related]  

  • 8. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination.
    Young MD; Gooch WM; Zuckerman AJ; Du W; Dickson B; Maddrey WC
    J Med Virol; 2001 Jul; 64(3):290-8. PubMed ID: 11424117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public health impact of Infanrix hexa™ (DTPa-HBV-IPV/Hib) reimbursement: A study programme in France. Part 2: Evolution of the acceptability of infants' vaccination against hepatitis B in general and pediatric practices - the PRALINE study.
    Vié le Sage F; Gaudelus J; Lert F; Dufour V; Texier N; Pouriel M; Schück S; Tehard B; Bréart G
    Rev Epidemiol Sante Publique; 2016 Jun; 64(3):185-94. PubMed ID: 27238163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sources of innovation: an assessment of intellectual property.
    Kinch MS; Raffo J
    Drug Discov Today; 2015 May; 20(5):500-4. PubMed ID: 25499663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination against hepatitis A and B: developments, deployment and delusions.
    Zuckerman JN
    Curr Opin Infect Dis; 2006 Oct; 19(5):456-9. PubMed ID: 16940869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization.
    Kane MA; Hadler SC; Lee L; Shapiro CN; Cui F; Wang X; Kumar R
    Vaccine; 2013 Dec; 31 Suppl 9():J15-20. PubMed ID: 24331015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution to hepatitis B prevention.
    Stephenne J
    Vaccine; 1992; 10(13):900-3. PubMed ID: 1471409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluations of hepatitis B vaccination for developing countries.
    Tu HA; Woerdenbag HJ; Kane S; Riewpaiboon A; van Hulst M; Postma MJ
    Expert Rev Vaccines; 2009 Jul; 8(7):907-20. PubMed ID: 19538116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates.
    Gunn TR; Bosley A; Woodfield DG
    N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public health perspective on vaccine-preventable hepatitis: integrating hepatitis A and B vaccines into public health settings.
    Hershey JH; Schowalter L; Bailey SB
    Am J Med; 2005 Oct; 118 Suppl 10A():100S-108S. PubMed ID: 16271550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region.
    Dolhain J; Janssens W; Sohn WY; Dindore V; Mukherjee P
    Expert Rev Vaccines; 2019 Sep; 18(9):921-933. PubMed ID: 31328999
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001.
    Van Damme P; Vorsters A
    J Med Virol; 2002 Jul; 67(3):433-9. PubMed ID: 12116040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
    Bar-On ES; Goldberg E; Hellmann S; Leibovici L
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD005530. PubMed ID: 22513932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.